Supplementary Figure S1 from Phase I Assessment of Safety and Therapeutic Activity of BAY1436032 in Patients with IDH1-Mutant Solid Tumors
Antje Wick,Oliver Bähr,Martin Schuler,Kristoffer Rohrberg,Sant P. Chawla,Filip Janku,David Schiff,Volker Heinemann,Yoshitaka Narita,Heinz-Josef Lenz,Masafumi Ikeda,Yuichi Ando,Wolfgang Wick,Joachim P. Steinbach,Michael C. Burger,Katharina Wenger,Ulrik Lassen,Kamalesh K. Sankhala,Cristiana Roggia,Isabelle Genvresse,Catya Munhoz,Christine Rentzsch,Susanne Reschke,Simon Langer,Markus Wagner,Stefan Kaulfuss,Charles Cai,Eleni Lagkadinou,Michael Jeffers,Carol Peña,Ghazaleh Tabatabai crossref（2023）
摘要
Supplementary Figure S1. Geometric mean plasma concentration-time profiles of BAY1436032 at dose levels of 150 mg to 1500 mg.
查看译文
AI 理解论文
溯源树
样例
